Literature DB >> 18578973

Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.

E Toussirot1, E Pertuiset, B Kantelip, D Wendling.   

Abstract

Anti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, giving favourable results. Thus, the occurrence of a granulomatous disease in a patient receiving such drug seems paradoxical. We describe 2 patients with inflammatory rheumatic disease, the first with ankylosing spondylitis, the second with rheumatoid arthritis, under anti-TNF-alpha treatment (infliximab and etanercept respectively) who developed non-caseating granulomas of the lungs and lymph nodes consistent with the diagnosis of sarcoidosis. Limited and various similar cases have been reported. It is generally considered that these granulomatous diseases are related to the anti-TNF-alpha agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18578973

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

1.  Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.

Authors:  Peter Korsten; Nadera J Sweiss; Ulf Nagorsnik; Timothy B Niewold; Hermann-Josef Gröne; Oliver Gross; Gerhard A Müller
Journal:  Am J Kidney Dis       Date:  2010-10-25       Impact factor: 8.860

Review 2.  Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature.

Authors:  Theoni Kanellopoulou; Anna Filiotou; Hariklia Kranidioti; Spyridon P Dourakis
Journal:  Clin Rheumatol       Date:  2010-10-23       Impact factor: 2.980

Review 3.  Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.

Authors:  Éric Toussirot; François Aubin
Journal:  RMD Open       Date:  2016-07-15

4.  Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature.

Authors:  Raquel Cuchacovich; Joseph Hagan; Tahir Khan; Arthur Richert; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

5.  Development of sarcoidosis following etanercept treatment: a report of three cases.

Authors:  Inger Marie Skoie; Klaus Wildhagen; Roald Omdal
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

Review 6.  Management of ankylosing spondylitis with infliximab.

Authors:  Éric Toussirot; Ewa Bertolini; Daniel Wendling
Journal:  Open Access Rheumatol       Date:  2009-06-17

7.  A Case of Adalimumab-Induced Granulomatous Interstitial Nephritis.

Authors:  Rory Plant; Adeel Rafi Ahmed; Teresa Mchale; Louise Giblin
Journal:  Cureus       Date:  2021-06-28

Review 8.  Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.

Authors:  Rosario Peluso; Giovanni Cafaro; Alessandro Di Minno; Salvatore Iervolino; Pasquale Ambrosino; Gelsy Lupoli; Matteo Nicola Dario Di Minno
Journal:  Clin Rheumatol       Date:  2013-04-16       Impact factor: 3.650

Review 9.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

10.  Certolizumab-induced uveitis: a case report and review of the literature.

Authors:  Elad Moisseiev; Shiri Shulman
Journal:  Case Rep Ophthalmol       Date:  2014-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.